Your browser doesn't support javascript.
loading
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta, Paola; Tavares-Da-Silva, Fernanda; Co, Maribel; Lecrenier, Nicolas; Hervé, Caroline; Stegmann, Jens-Ulrich.
Affiliation
  • Pirrotta P; GSK, Avenue Fleming 20, 1300, Wavre, Belgium. paola.x.pirrotta@gsk.com.
  • Tavares-Da-Silva F; GSK, Avenue Fleming 20, 1300, Wavre, Belgium.
  • Co M; GSK, Avenue Fleming 20, 1300, Wavre, Belgium.
  • Lecrenier N; GSK, Avenue Fleming 20, 1300, Wavre, Belgium.
  • Hervé C; GSK, Avenue Fleming 20, 1300, Wavre, Belgium.
  • Stegmann JU; UCB Pharma, Chemin du Foriest 1, 1420, Braine-l'Alleud, Belgium.
Drug Saf ; 44(12): 1341-1353, 2021 12.
Article in En | MEDLINE | ID: mdl-34622421
Shingles is a disease caused by reactivation of the chickenpox virus. It mostly affects adults aged 50 years and older and patients of all ages who have an impaired immune system. Diagnosis of shingles is often based only on the presence of symptoms such as a typical rash and pain. However, rashes can have various other causes (e.g., allergies, autoimmune diseases, and infections). Consequently, rashes with other causes may be misdiagnosed as shingles. Adults at increased risk of shingles and/or aged 50 years and older may be vaccinated with Shingrix (GSK, Belgium) to protect them from shingles and its complications. Since Shingrix became available in Germany, blister-like skin rashes have been reported that occurred shortly after vaccination. We searched the GSK safety database for reports of blister-like skin rashes that occurred following vaccination with Shingrix and that were spontaneously reported from countries where Shingrix was first marketed. To analyse these reports of rashes, we described the reports that we retrieved, we performed a statistical analysis to quantify whether the number of events assessed as reactivations of the chickenpox virus following Shingrix vaccination was higher than the number of reactivations that would be expected in the general population, and we described possible explanations for the observed rashes and underlying disease mechanisms. Our analyses did not raise safety concerns related to the onset of these rashes after vaccination with Shingrix. This paper raises awareness about the varying causes of rashes since a shingles-like rash that onsets shortly after vaccination with Shingrix is not necessarily caused by vaccination. In conclusion, this analysis shows that caution is needed when evaluating rashes in older adults and that all potential contributing factors (e.g., pre-existing diseases, medication, vaccination) should be considered.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Herpes Zoster Vaccine / Herpes Zoster Type of study: Prognostic_studies Limits: Humans Language: En Journal: Drug Saf Journal subject: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Year: 2021 Type: Article Affiliation country: Belgium

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Herpes Zoster Vaccine / Herpes Zoster Type of study: Prognostic_studies Limits: Humans Language: En Journal: Drug Saf Journal subject: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Year: 2021 Type: Article Affiliation country: Belgium